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This paper presents an improved, comprehensive liquid chromatography-electrospray-mass
spectrometry (LC-ES-MS) general unknown screening (GUS) procedure for drugs and toxic
compounds and its comparison with conventional techniques in routine laboratory conditions.
Chromatographic separation involved an X-TERRA MS C18, 3.5 m (100 mm  1 mm i.d.)
column together with a 25-min long gradient of acetonitrile in pH 3, 2 mM ammonium formate
delivered at a 50 l/min flow rate. Two different in-source collision-induced dissociation
voltages were alternated, both in the positive and in the negative ion modes. Reconstructed
spectra were then obtained in both polarities by adding up spectra obtained with low and high
energy, resulting in spectra presenting a sufficient number of specific fragment ions for
unambiguous and fast identification of compounds. Two large mass spectral libraries of drugs
and toxic compounds were built and an efficient automated signal processing, library
searching and report editing algorithm developed. Using a common, efficient solid-phase
extraction procedure, this LC-ES-MS technique was compared to GC-MS and HPLC-DAD
GUS procedures for the identification of a priori unknown compounds in 51 serum samples
consecutively sent to the laboratory for GUS. The present LC-MS method identified 75% of the
compounds contained in these samples (versus 66% for GC-MS and 71% for HPLC-DAD),
including 8% that the other two techniques failed to identify (versus 8% for GC-MS and 9.5%
for HPLC-DAD). Therefore, it is complementary to GC-MS and/or HPLC-DAD and helps
enlarge the range of drugs detected in clinical toxicology. It could be useful as well in forensic
toxicology to confirm a positive result, as 38% of all the compounds were detected by the three
techniques and 36% by two of them. (J Am Soc Mass Spectrom 2003, 14, 14–22) © 2003
American Society for Mass Spectrometry
What clinical and forensic toxicologists expectfrom a general unknown screening (GUS)procedure is the unambiguous identification
of the xenobiotics involved in intoxication cases, even
when they have no clues to guide the search. Auto-
mated immunoassays generally represent a first ap-
proach and provide a result in a few minutes, but these
techniques allow, for most of them, only a class-diag-
nostic, notwithstanding the limited number of classes
available.
On the contrary, chromatographic techniques cou-
pled to specific detectors such as mass spectrometers or
UV-diode array detectors cover a very large panel of
relevant compounds [1–4]. Nevertheless, the limited
specificity of UV spectra (since several compounds can
have similar UV-spectra), their variability as a function
of pH and the fact that a lot of compounds present poor
or no UV absorbance, make HPLC-UV-DAD not very
specific, reliable, nor universal. Thus, very few UV
spectrum libraries are commercially available. On the
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contrary, due to its widespread availability and its high
specificity, gas chromatography/mass spectrometry (GC-
MS) is considered as being the gold standard technique
for general unknown screening in toxicology. It is based
on electron ionization (EI) with standard conditions (70
eV) for which very large EI-mass spectra libraries exist [1,
2]. However, due to the gas phase properties, GC-MS
presents some weak points. It requires time-consuming
extraction procedures and sometimes cleavage of conju-
gates prior to extraction. Drugs or metabolites can be
detected in their native form only if they are thermally
stable, volatile, and mildly or nonpolar. Furthermore,
derivatization and artifact formation significantly compli-
cates the identification process [5].
For these reasons, liquid chromatography-mass spec-
trometry (LC-MS) which uses both an almost universal
separation process and the most specific and sensitive
type of detector, is a promising, alternative approach to
GC-MS and HPLC-DAD [5, 6]. Though electrospray
ionization sources entail a soft ionization process, al-
most as much fragmentation can be obtained using
in-source collision induced dissociation (CID) as with
CID in the collision cell of a MS-MS system.
Recently the first complete, standardized, auto-
mated, and routinely applicable GUS procedure for
drugs in serum based on LC-ES-MS, using in-source
CID at various orifice voltages, both in the positive and
negative ionization modes [7–9] was reported. Using
this procedure, two CID-MS spectra libraries were built:
One library comprising of about 1100 reconstructed
mass spectra in the positive mode, and another of about
500 mass spectra in the negative mode. Each of these
so-called reconstructed spectra was obtained by adding
up one spectrum obtained at low (20 V) and one
obtained at high (80 V) fragmentation voltage, and thus
presented, in addition to the molecular or protonated
ion, a sufficient number of fragment ions to allow
efficient and specific compound identification.
To the best of our knowledge, no other such com-
prehensive LC-ES-MS screening procedure has been
proposed up till now, although an increasing number of
papers concerning the application of LC-MS to forensic
and clinical toxicology have been published in the last
two years [10–17]. However, the analytical time of this
procedure was still too long (1 h) to be used routinely in
a clinical toxicological laboratory.
This paper presents an improved LC-ES-MS general
unknown screening procedure and an evaluation of the
performance of this technique by comparison with that
of classical GC-MS and HPLC-DAD GUS procedures,
using a common efficient extraction procedure for the
three techniques.
Materials and Methods
Standards and Reagents
Organic solvents and reagents were all of analytical
grade. Acetonitrile and methanol were obtained from
Carlo Erba (Milan, Italy), formic acid, ammonium for-
mate and potassium phosphate from Sigma (St. Louis,
MO). Deionized water was prepared on a MilliQ labo-
ratory plant (Millipore, Bedford, MA). Glafenin was
purchased from Sigma (St. Louis, MO). Quality control
serum samples (Therapeutic Drug Monitoring Control
Level 1) were obtained from BIO-RAD (Ivry-sur-Seine,
France). Oasis MCX extraction cartridges were pur-
chased from Waters (St. Quentin-en-Yvelines, France)
and prepacked NT1 Extrelut from Merck KgaA (Darm-
stadt, Germany).
Sample Preparation Procedures
Reference solid-phase extraction prior to the GC-MS screen-
ing procedure. One mL of serum was acidified by
addition of 1 mL 0.1N HCl and deposited on a pre-
packed NT1 Extrelut column (diatomaceous earth
phase). 1 mL of serum was alkalized by addition of 1
mL pH 9.7 sodium carbonate buffer, then loaded on
another prepacked Extrelut NT1 column. These two
samples were extracted by addition of 10 mL dichlo-
romethane to each cartridge. The two extracts were then
mixed, evaporated to dryness (nitrogen gas at 70 °C)
and finally redissolved in 100 L of 40 mg/L protryp-
tiline (I.S.) methanolic solution.
Reference liquid-liquid extraction prior to the HPLC-DAD
screening procedure. A mixture of 0.5 mL serum, 0.5 mL
pH 9.5 NH4Cl/deionized water (30:70, vol/vol) and 25
L of a methylclonazepam (I.S.) solution at 50 mg/L
was vortex-mixed and extracted by addition of 8 mL of
CH3Cl/2-propanol/heptane (60:14:26 vol/vol/vol).
The organic phase was evaporated to dryness at 37 °C
and the residue dissolved in 50 L methanol/water
(50:50 vol/vol).
Evaluation of the common solid-phase extraction for the three
GUS techniques. A common procedure for the isolation
of compounds from biologic matrices prior to LC-MS,
GC-MS, and HPLC-DAD GUS procedures was devel-
oped. One mL of serum was deposited on an Oasis
MCX, mixed-mode phase extraction cartridge contain-
ing both hydrophobic polymers and sulfonic acid (cat-
ion exchange) functional groups, previously condi-
tioned with 1 mL methanol and 1 mL deionized water.
After rinsing the cartridge with 1 mL 0.1 N hydrochloric
acid, elution was performed with 1 mL of a methanol-
ammonium hydroxide solution (25%) (98:2 vol/vol)
mixture. The extract was divided into three parts that
were evaporated to dryness under a nitrogen stream at
room temperature. For the LC-MS procedure, the dry
extract was dissolved in 100 l of a deproteinated
serum/acetonitrile (50:50 vol/vol) mixture, obtained by
adding 100 L glafenin (I.S.) working solution in ace-
tonitrile to 100 L serum, followed by vortex-mixing
and centrifugation (some deproteinated serum was thus
added to the dry extract with the aim of increasing the
recovery of the most hydrophilic drugs). This addition
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of deproteinated serum was not applied to the two
other techniques as it resulted in a dramatic increase in
background noise on UV and E.I. spectra. For GC-MS,
the dry extract was reconstituted with 100 L of 40
mg/L protriptyline (I.S.) methanolic solution. For
HPLC-DAD, the dry extract was reconstituted in meth-
anol/water (50:50 vol/vol) containing methylclonaz-
epam (I.S.) at 50 mg/L.
In order to validate for GC-MS and HPLC-DAD this
SPE procedure initially developed for LC-MS, a study
was carried out using 51 serum samples sent to the lab
by adult and pediatric emergency departments for
suspected intoxication or acute poisoning cases. Both the
usual reference extraction methods for GC-MS and HPLC-
DAD and the present SPE procedure were performed in
parallel. The results obtained by GC-MS and HPLC-DAD
with the candidate SPE were compared to those obtained
with the respective reference extraction methods.
LC-MS Method
The chromatographic system consisted of a Series
200LC micro-flow rate, high pressure gradient pump-
ing system, and a Series 200 Auto-sampler (Perkin-
Elmer Instruments, Les Ulis, France) including a Rheo-
dyne model 7725 injection valve equipped with a 5 l
internal loop. Chromatographic separation was per-
formed on a X TERRA MS C18 3.5 m (100 mm  1 mm
i.d.) column (Waters, St. Quentin-en-Yveline, France),
using a linear gradient of acetonitrile (ACN) in 2 mM,
pH 3.0 ammonium formate, as mobile phase (constant
flow-rate 50 L/min), programmed as follows: 0–1
min, 5% ACN; 1–20 min, 10 to 90% ACN; 21–22 min,
90% ACN; 22–22.5 min, decrease from 90 to 5% ACN;
22.5–25.5 min, column equilibration with 5% ACN.
Mass spectrometric analyses were conducted using
an API 100 single quadrupole instrument (Applied
Biosystem-Sciex, Concord, Canada), equipped with a
pneumatically assisted electrospray (Ionspray) ioniza-
tion source. The whole system was controlled using a
G3 Power Macintosh computer equipped with
LC2Tune, MultiView 1.4 and Sample Control 1.1 soft-
ware (Applied Biosystem-Sciex). Ionization in the Ion-
spray source was performed in the positive and nega-
tive modes, scanning masses from m/z 100 to 1100, with
a 0.2 u step size. In the positive mode, ionization voltage
was 5500 V, Q0 10 V, ring 275 V, orifice (fragmen-
tation) voltages 20 V and 80 V; in the negative
mode, ionization voltage was 4500 V, Q0 10 V, ring
250 V, orifice voltages 20 V and 80 V. The influ-
ence of the fragmentation energy and ion-source geo-
metrical configuration on ionization and fragmentation
efficiency were shown in previous studies [8, 9], and the
optimal distance between the ionization needle and the
mass spectrometer entrance orifice found to be approx-
imately 6 mm. However, before each experiment, this
distance was finely adjusted to obtain a reference frag-
mentation spectrum of glafenin (test compound) and to
provide a good reproducibility of compound fragmen-
tation.
These four ionization conditions resulted in four
chromatograms corresponding to each polarity and
fragmentation voltage value. Positive and negative
reconstructed spectra were obtained by adding, in the
centroid mode (merge distance 1 u, minimum width
1 u) spectra at 20 V and 80 V on the one hand and
spectra at 20 V and 80 V on the other. These four
acquisition conditions were looped. In order to obtain
a sufficient number of points for each chromato-
graphic peak and so enable their efficient detection
and integration, the shortest convenient dwell time
was found to be 0.06 ms (actual count time for each
step in the mass range). Below this value, a loss of
signal intensity was noted. So each scan in the
100 –1100 u range was 1.21 s long. The “polarity-
switching time”, corresponding to the time required
by the instrument for switching from one ionization
polarity to the other, was set at 0.9 ms. Attempts to
reduce this value further resulted in a dramatic loss
of signal intensity. Finally, the 30 min-long chromato-
gram corresponded to 589 iterations of a 3.055 s long
loop.
GC-MS and HPLC-DAD Methods
Briefly, GC-MS was performed using a model 5890
gas chromatograph (Hewlett-Packard, Les Ulis,
France) equipped with a glass needle injector and a
PTE, 30 m  0.32 mm i.d., 0.25 m film thickness
capillary column (Sigma, St. Quentin Fallavier,
France). Oven temperature was programmed from
110 to 220 °C at 20 °C/min, from 220 to 260 °C at
2 °C/min, up to 280 °C at 10 °C/min, maintained for
15 min. The injector and interface temperatures were
270 and 280 °C, respectively. A MSD 5972 mass
spectrometer (Hewlett-Packard, Les Ulis, France) was
used as a detector, operated in the electron ionization
mode at 70 eV, scanning masses from 440 to 510 u at
a speed of 2.5 scans/s. An in-house as well as two
commercial electronic libraries of EI mass spectra
(PMW-Tox2 [1] and Wiley 7N [18]) were used for
compound identification.
HPLC-DAD was performed using a LC10A high
pressure binary gradient pumping system (Shimadzu,
Duisburg, Germany) a Nucleosil C18, 5 m (150  4.6
mm i.d.) stainless steel column together with a gradient
of ACN in pH2.6, 25 mM potassium phosphate buffer
(15% ACN for 2 min, increased linearly to 75% in 40
min, then to 90% in 3 min, maintained for 3 min) delivered
at a constant flow rate of 1.3 mL/min. Detection was
performed using a Shimadzu SPDM 10A diode array
spectrophotometer, scanning the 200–400 nm wavelength
range with a 1 nm resolution. An in-house library of over
1500 UV spectra of drugs, toxic compounds and metabo-
lites was used for compound identification.
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Comparison Between LC-MS, GC-MS and HPLC-
DAD GUS Procedures
Each of the 51 serum samples were extracted following
the common, validated SPE procedure described above
then analyzed using GC-MS, HPLC-DAD and LC-MS
within a 48 h period. The qualitative results (number
and nature of compounds detected) obtained with the
three different analytical procedures were used to eval-
uate their respective performance, considering as refer-
ence the combination of these three techniques (i.e., the
compounds supposed to be present in each clinical
sample were those found by at least one of these
techniques).
Results and Discussion
What can be expected from a general unknown screen-
ing procedure is the unambiguous identification of a
very large range of drugs, poisons, pesticides, and
metabolites. It requires a good sensitivity and a high
specificity. However, an effective nontarget analysis
should also be as fast as possible, especially when the
need for accurate information is urgent. The present
LC-ES-MS technique allows highly polar to highly
nonpolar compounds to be separated using a 30 min
chromatographic run. As an example, a chromatogram
is presented in Figure 1, corresponding to a blank
serum sample obtained from a healthy volunteer and
spiked at 10 mg/L with the highly polar morphine-6-
glucuronide, the mildly polar pholcodine, the highly
lipophilic amiodarone, and fenpropathrin (an insecti-
cide), with glafenin as internal standard. The LC-front
peak was found at 1.7 min whereas morphine-6-gluc-
uronide was eluted at about 5 min. Amiodarone and
fenpropathrin were eluted in 18 min and 22.5 min
respectively, compared to about 45 min under the
previously published chromatographic conditions [9].
Electrospray ionization sources entail a soft ioniza-
tion process. So, spectra obtained are known to be
poorly informative since very few or no fragment ions
are produced by this process. The best solution found to
obtain rich, specific, and informative mass spectra was
to create “reconstructed” spectra by adding up two
spectra acquired with low and high fragmentation
energies, respectively, which in most cases contained
both the protonated molecule (20 V) and several
fragment ions (80 V).
A general unknown screening procedure must be
able to detect and identify basic, acidic, or neutral
unexpected compounds within a large range of lipid
solubility. Thus, it requires a nonclass-specific extrac-
tion procedure able to isolate the widest range of
relevant molecules from biological matrices. Such pro-
cedures may involve a single liquid–liquid extraction,
two liquid–liquid extractions in parallel (one for acidic
and one for basic compounds) [11, 12], solid-phase
extraction with classical hydrophobic C18 bonded
phase [13], or mixed-mode phase SPE [13–16]. The
Oasis MCX extraction cartridges used for the present
study involve both reverse phase retention on a poly-
meric support and strong cation exchange properties,
thus increasing the polarity range of extracted com-
pounds. However, to increase the recovery of hydro-
philic compounds, generally poorly retained on SPE
cartridges, some serum deproteinated with acetonitrile
was added to the dry extract (instead of dissolving it
with ammonium formate and acetonitrile). The protein
precipitation step by dilution 1/2 in acetonitrile re-
sulted in a theoretical 1/2 dilution of hydrophilic com-
pounds in the supernatant, but the toxic levels of
hydrophilic compounds are generally much higher than
those of lipid soluble drugs.
A first hint of the efficiency of the present compre-
hensive LC-MS GUS method, including automated sig-
nal processing and library searching, was given by the
analysis of an extract of a commercial internal quality
control (IQC) for therapeutic drug monitoring (TDM
Control Level 1, BIO-RAD, Ivry-sur-Seine, France). This
IQC consists of a pool of blank serum spiked with
different drugs at known, low therapeutic concentra-
tions (i.e., lowest levels on a scale of three) [19] and is
used to check the accuracy of the analytical techniques
employed for these molecules. Thirteen of the 27 drugs
and metabolites contained at these low therapeutic
levels were identified (see Table 1 and Figure 2), includ-
ing acidic (e.g., acetaminophen, phenobarbital, and sal-
icylic acid) as well as basic (e.g., amitriptyline, phenyt-
oin) drugs. Acidic drugs with a low pKa may not show
up in the positive ionization mode. For example, sali-
cylic acid present in the IQC sample at a concentration
of 260 mg/L was only detected in the negative ioniza-
tion mode, at a retention time of 10.9 min. Thus,
libraries of negative spectra are indispensable for acidic
compounds that may not be detected in the positive
ionization mode and are hardly amenable to GC-MS
without derivatization. In the best cases, positive and
negative spectra can both be identified in the respective
libraries and confirm each other. They can also be useful
Figure 1. Total Ion Current (TIC) chromatogram obtained from a
blank serum spiked with morphine-6-glucuronide, pholcodine,
amiodarone, and fenpropathrin (insecticide) at 10mg/l, in the
positive single full-scan (100 to 1100 u) mode.
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to determine the molecular weight of a compound not
recorded in the libraries.
On the raw, total-ion current (TIC) chromatogram
shown in Figure 2, some peaks appear with very low
intensity, owing to their low concentration but also to
the high background noise obtained in the scan mode.
However, this limitation was overcome by using the
previously described “enhance” function available on
the Mac version of the software [9] that allowed the
detection of closely eluted or low-intensity peaks (e.g.,
peak at 11.7 min in Figure 2).
Finally, the wide range of molecules positively iden-
tified at low therapeutic serum concentration in this
sample is a first argument in favor of the efficacy of this
comprehensive method. However, amikacin, cyclospor-
ine, digoxin, ethosuximide, flecainid, gentamycin, lido-
caine, methotrexate, netilmicin, tobramycin, caffeine,
desipramine, nortriptylin, and propranolol were not
identified at these low concentrations.
Comparison Between LC-ES-MS, HPLC-DAD and
GC-MS Screening Procedures
Validation of the common solid-phase extraction proce-
dure. Fifty-one serum samples sent to our lab in a
clinical or forensic context were analyzed in parallel
with the reference extraction methods (LLE in alkaline
conditions for HPLC-DAD and double acidic/basic
extraction on NT1 Extrelut for GC-MS) and with the
SPE procedure using Oasis MCX cartridges. Overall, 78
hits corresponding to 39 different compounds of toxi-
cological interest were found. For each serum sample
analyzed, the results were identical with the tested SPE
procedure and the reference ones, except in two cases:
Bromazepam and midazolam were not detected by the
tested SPE in one sample each. However, these two
particularly unstable benzodiazepines might have been
degraded because of the delay (which could reach 48 h)
between the first routine analysis using the usual refer-
ence extraction procedure and the second assay involv-
ing the new SPE method. Moreover, they were gener-
ally correctly identified in other samples using the
candidate SPE (Table 2). Another explanation might be
Table 1. Efficacy of the LC-MS procedure for detecting and identifying compounds in a commercial quality control for therapeutic
drug monitoring (Therapeutic Drug Monitoring Control Level 1, BIO RAD, Ivry-sur-Seine, France)
Compound
Molecular
weight
Retention
time min
Ions with
positive
ionization m/z
Ions with the
negative
ionization
m/z
Concentration
level mg/L
Therapeutic
plasma
concentration
(less than)
mg/L (19)
Plasma
concentration
leading to serious
toxicity mg/L (19)
Procainamide 235.79 6.18 236.8; 163;
120
/ 2.1 8 12
Acetaminophen 151.20 6.26 152; 110 150 13 30 200
Theophylline 180.20 7.64 181; 124 179; 164; 137 4.8 20 40
Quinidine 324.43 8.19 325.6; 253;
172
/ 1.3 5 8
Disopyramide 339.47 8.84 341.4; 239;
195
/ 0.8 5 8
Primidone 218.26 9.11 219.2; 162;
199
/ 2.9 12 40
Salicylic acid 138.12 11.70 / 137.4 260 300 400
Phenobarbital 319.89 11.22 271; 250 232; 306 9.4 40 100
Chloramphenicol 323.14 11.35 324; 305; 275 321; 257; 194 5.8 25 40
Imipramine 280.40 12.30 281.2; 208;
193
/ 0.122 0.3 1
Amitriptyline 277.39 12.60 279.3; 218;
191
/ 0.084 0.3 1
Phenytoin 252.26 12.92 253.2; 225;
182
251; 199 7.2 20 40
Carbamazepine 236.26 13.10 237.1; 194;
179
/ 2.8 12 30
Figure 2. Zoomed view of a LC-MS total ion chromatogram
obtained from an extract of a commercial quality control for
therapeutic drug monitoring (Bio-Rad, TDM 1). Bold line: Raw
TIC chromatogram. Doted line: Enhanced, positive ion TIC chro-
matogram. Thin line: Enhanced, negative ion TIC chromatogram.
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Table 2. Therapeutic drugs and toxic compounds detected in 51 serum samples using HPLC-DAD and GC-MS following a common
SPE method as compared with the reference extraction techniques
Sample
GC-MS HPLC-DAD
Reference LLE Common SPE Reference LLE Common SPE
1 Acetaminophen Acetaminophen Acetaminophen Acetaminophen
2 Zolpidem Zolpidem Zolpidem Zolpidem
3 Mianserine, methadone Mianserine, methadone Citalopram, methadone,
EDDP
Citalopram, methadone, EDDP
4 Acetaminophen, valproic
acid, phenobarbitone,
phenytoin
Acetaminophen, valproic
acid, phenobarbitone,
phenytoin
Acetaminophen Acetaminophen
5 ND ND ND ND
6 Meprobamate,
acetaminophen,
zolpidem
Meprobamate,
acetaminophen, zolpidem
Bromazepam,
acetaminophen, zolpidem
Bromazepam, acetaminophen,
zolpidem
7 Acetaminophen Acetaminophen Acetaminophen Acetaminophen
8 ND ND ND ND
9 ND ND Cetirizine, salicylic acid Cetirizine, salicylic acid
10 Acetaminophen Acetaminophen Acetaminophen Acetaminophen
11 ND ND Clorazepate dipotassium Clorazepate dipotassium
12 ND ND ND ND
13 ND ND Clorazepate dipotassium Clorazepate dipotassium
14 Acetaminophen Acetaminophen Norldiazepam,
acetaminophen
Nordiazepam, acetaminophen
15 Bromazepam ND Bromazepam ND
16 Ibuprofen, niflumic acid Ibuprofen, niflumic acid Niflumic acid, indomethacin Niflumic acid, indomethacin
17 Phenobarbitone, 7
aminoflunitrazepam
Phenobarbitone, 7-
aminoflunitrazepam
Phenobarbitone, 7-
aminoflunitrazepam
Phenobarbitone, 7-
aminoflunitrazepam
18 ND ND Cefoxitin Cefoxitin
19 Acetaminophen,
dextropropoxyphen,
diazepam, nordiazepam
Acetaminophen,
dextropropoxyphen,
diazepam, nordiazepam
Acetaminophen,
dextropropoxyphen,
diazepam, nordiazepam
Acetaminophen,
dextropropoxyphen,
diazepam, nordiazepam
20 Midazolam Midazolam Midazolam Midazolam
21 Acetaminophen Acetaminophen Acetaminophen Acetaminophen
22 ND ND ND ND
23 Nordiazepam,
phenobarbitone
Nordiazepam,
phenobarbitone
Nordiazepam Nordiazepam
24 Cyamemazine Cyamemazine Cyamemazine, oxazepam Cyamemazine, oxazepam
25 ND ND ND ND
26 ND ND Oxazepam Oxazepam
27 Nordiazepam Nordiazepam Nordiazepam Nordiazepam
28 Midazolam, lidocain Midazolam, lidocain Midazolam Midazolam
29 Levomepromazine Levomepromazine ND ND
30 ND ND Propafenone Propafenone
31 ND ND Clorazepate dipotassium Clorazepate dipotassium
32 Acetaminophen Acetaminophen Acetaminophen,
furosemide, midazolam
Acetaminophen, furosemide
33 ND ND Piroxicam Piroxicam
34 Nordiazepam Nordiazepam Nordiazepam Nordiazepam
35 ND ND Flecainide Flecainide
36 Acetaminophen Acetaminophen Acetaminophen Acetaminophen
37 Clonazepam Clonazepam Clonazepam Clonazepam
38 Acetaminophen,
amitriptyline
Acetaminophen,
amitriptyline
Acetaminophen,
amitriptyline
Acetaminophen, amitriptyline
39 Lidocain Lidocain ND ND
40 Hydroxychloroquine Hydroxychloroquine ND ND
41 Fluoxetine Fluoxetine Fluoxetine, piroxicam Fluoxetine, piroxicam
42 Phenobarbitone,
mianserin
Phenobarbitone, mianserin Mianserin Mianserin
43 Nordiazepam Nordiazepam Nordiazepam, oxazepam Nordiazepam, oxazepam
44 ND ND Clorazepate dipotassium Clorazepate dipotassium
45 Acetaminophen,
phenobarbitone
Acetaminophen,
phenobarbitone
Acetaminophen Acetaminophen
46 ND ND Citalopram Citalopram
Continued
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that of the difference in sample volume for the two
extraction procedures: the classical LLE prior to HPLC-
DAD requires 2 mL of serum, whereas the tested SPE
uses only 1 mL for the three techniques (extract divided
into three equal parts before evaporation), i.e., 1/3 mL
for each. However, it was not possible to confirm that
these benzodiazepines were at a low concentration in
these particular samples, as our GUS procedures are not
quantitative.
The discrepancies between the different chromato-
graphic/detection techniques are addressed in the fol-
lowing section, considering only the case where a
common extraction method is used.
Study of 51 serum samples from routine clinical toxicology
activity. The three methods were compared for the
analysis of the same 51 serum samples as above, con-
sidering only the common, nonselective solid-phase
extraction method developed for the present study.
Eighty-four hits (corresponding to 46 different com-
pounds) were detected at least by one of these three
techniques. The results are summarized in Figure 3.
Sixty-three hits (75%) were obtained with LC-ES-MS,
compared to 55 (65.5%) with GC-MS, and 60 (71.4%)
with HPLC-DAD. Of note, it corresponds to the detec-
tion of 39 different compounds by LC-MS compared to
27 and 32 by GC-MS and HPLC-DAD, respectively.
About 8% of all hits were obtained by LC-MS alone, i.e.,
exactly the same percentage as by GC-MS, compared to
9.5% by HPLC-DAD. Therefore, none of these three
analytical techniques can be considered as universal,
and combining at least two of them significantly broad-
ens the panel of compounds identified in many sam-
ples. Another interesting finding is that some of the
compounds identified by only one technique were
actually detected (but not positively identified) by an-
other one at least. For instance, simvastatine, which
belongs to the class of statine drugs against hypercho-
lesterolemia, could only be positively identified by
LC-MS because its UV and EI spectra were not specific
enough to ascertain which compound it was in the
statine class. Indeed, its 70 eV EI mass spectrum does
not show the protonated molecule, contrary to the
reconstructed in-source CID spectrum. Simvastatine
could be identified by its positive reconstructed MS that
exhibits its molecular ion (m/z 419.6), adducts of its
molecular ion (m/z 437.0), and of its dimer (m/z 855.6)
with ammonium, as well as several fragment ions. It
could also be identified by its negative reconstructed
spectrum, showing formate adducts of its molecular ion
(m/z 464.2) and its dimer (m/z 882.8) (Figure 4). Noscap-
ine could also be identified by LC-MS owing to the
“enhance” function that significantly increased the
signal-to-noise ratio of its reconstructed spectrum,
whereas its UV and EI spectra could not be obtained
with sufficient purity to reach good enough similarity
with the spectra in the respective libraries.
Finally, 38.1% of all compounds could be identified
simultaneously by the three techniques and 35.6% by
two techniques, which is interesting in clinical toxicol-
ogy and essential if the present technique is to be
adapted to forensic toxicology, where, as in some coun-
tries, the positive identification of a suspected com-
pound requires to be achieved using two different
techniques.
Of note, the GC-MS GUS method used does not
include any derivatization of the extracts, which would
have probably increased the number of compounds
detected by this technique, as abundantly demonstrated
by Maurer et al. [1, 2, 20]. Nevertheless, we think that
even the best derivatization procedure would not allow
for the detection of all the compounds, such as chlora-
lose or methotrexate for instance, that were only de-
tected by LC-MS in the present study. The addition of
deproteinated serum to the dry extract prior to LC-MS
and not to the other two techniques probably did not
play a significant role in the differences noted between
Table 2. Continued
Sample
GC-MS HPLC-DAD
Reference LLE Common SPE Reference LLE Common SPE
47 ND ND Moclobemide Moclobemide
48 ND ND Clobazam Clobazam
49 Phenobarbitone,
carbamazepine
Phenobarbitone,
carbamazepine
Carbamazepine Carbamazepine
50 ND ND ND ND
51 Ethosuximide Ethosuximide Chloramphenicol Chloramphenicol
Figure 3. Comparison of LC-MS, GC-MS and HPLC-DAD in 51
clinical serum samples analyzed using three general unknown
screening techniques preceded by a common SPE procedure.
Number of occurrences are noted in brackets.
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these techniques in the present study as we checked
that even the most hydrophilic compounds such as
chloralose and methotrexate were present in the dry
extract. However, this additional step could be useful
for other compounds and should not be considered as a
bias in the present study, because it is only possible
with LC-MS and is one of the advantages inherent to
this technique. The aim was to compare complete,
routine analytical procedures using as many common
steps as possible but not to handicap any one of these
by standardizing too many of these steps.
The comparison of LC-MS, GC-MS and HPLC-DAD
GUS procedures presented herein is still preliminary, as
51 serum extracts cannot be representative of the activ-
ity of a clinical toxicology lab. However, these results
suggest that the present comprehensive LC-ES-MS GUS
technique is efficient (detection of 75% of all com-
pounds) and complementary to GC-MS (percentage of
compounds detected increased by 24.9%) and HPLC-
DAD (percentage increased by 20.2%). In our lab, the
three analytical techniques are now employed simulta-
neously in routine work.
Conclusion
In-source CID has been used by several teams using
different ionization and fragmentation conditions [14,
17]. To the best of our knowledge, they used two or
three different fragmentation voltages and built dif-
ferent libraries corresponding to these fragmentation
conditions. The originality of the procedure devel-
oped in our laboratory is the use of “reconstructed”
and much more informative spectra obtained by
adding a pair of spectra, one without and one with
fragment ions, in both the positive and the negative
modes [8, 9].
On the basis of this previously developed LC-ES-MS
general unknown screening procedure, improvements
were introduced into the present study, one of which is
the reduction of total chromatographic time to 30 min,
which is an obvious advantage for clinical toxicology
which requires accurate and fast information, with
preserved resolution and peak width thus allowing
automatic peak detection, integration, and compound
identification. The solid-phase extraction method based
on a mixed-mode support developed for LC-MS was
shown to be as efficient as those routinely used in our
laboratory for GC-MS and HPLC-DAD. Moreover, it
requires a limited sample volume (1 mL), a single
cartridge for the three techniques, and substantially
shortens the total analytical time. A comparative study
using clinical serum samples suggested that this com-
prehensive LC-MS GUS procedure was efficient enough
to be used routinely and was complementary to GC-MS
and HPLC-DAD, making the combination of these three
techniques a global GUS strategy able to detect the
widest range of therapeutic drugs and toxic com-
pounds.
However, the lack of inter-instrument robustness
of LC-MS as a GUS technique still limits its wide-
spread use. Though it is possible to standardize
fragmentation intensity on a given instrument and on
instruments with identical ionization sources by us-
ing a reference compound (e.g., glafenin in the
present study), it was recently shown that it was not
possible to reproduce the same fragmentation inten-
sity for all compounds using different types of instru-
ments, i.e., electrospray-type sources with different
configuration/geometry [21, 22]. It suggests that dif-
ferent mass spectral libraries should be built for the
different types of ionization sources. However, the
differences found only concerned the relative inten-
sity of ions in the mass spectra, not their nature.
Moreover, in all instances, the molecular or pseudo-
molecular ions and several fragments were present in
the mass spectra. So, as our procedure attributes only
small weight [9] to relative intensity, the apparent
lack of robustness between different brands of instru-
ments might not be insurmountable and requires
further studies.
Figure 4. Building-up of simvastatine positive (C) and nega-
tive reconstructed spectrum (C) obtained by adding raw spectra
acquired at fragmentation voltages 20 V (A or A) and 80 V
(B or B), respectively.
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